Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
27.00
-1.24 (-4.39%)
Bozor ochiq: Aug 12, 2026, 11:24 AM EDT
29.82
+1.58 (5.61%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Cue Biopharma, Inc., klinik bosqichdagi terapevtik kompaniya, immunologik kasalliklarni davolashning turli usullarini ishlab chiqishga qaratilgan. Kompaniyaning asosiy aktivlari CUE-221 hisoblanadi, bu allergik kasalliklar uchun 2-bosqich rivojlanishida bo'lgan er-xotin mexanizmga ega bo'lgan anti-IgE antitelasi. Kompaniya, shuningdek, Immuno-STAT platformasini ishlab chiqdi, u keng miqyosdagi immunitetni modulyatsiya qilmasdan, kasallikka xos T-hujayralarini in vivo nishonga oladi. Kompaniyaning asosiy avtoimmunitet nomzodlari CUE-401 hisoblanadi, bu IL-2 va TGF-B ning ikki funksiyali dasturi bo'lib, yallig'lanishni tartibga solish va Treg vositachiligidagi tolerantlikni rag'batlantirish uchun 1-bosqich rivojlanishiga qarab harakat qilmoqda. Kompaniya ilgari Imagen Biopharma, Inc. nomi bilan tanilgan va 2016-yil oktyabr oyida Cue Biopharma, Inc. nomiga o'zgargan. Cue Biopharma, Inc. 2014-yilda tashkil etilgan va Massachusets shtatining Boston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
| Dr. Rodolfo Jose Chaparro Ph.D. | Co-Founder |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Shao-Lee Lin M.D., Ph.D. | President, CEO & Director |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
| Mr. Colin G. Sandercock J.D., MSE | Senior Vice President of Intellectual Property |
| Mr. James M. Ahlers | Chief Financial Officer |
| Ms. Agnes Lee | Chief Officer of Public & Investor Relations |
| Ms. Lucinda Warren | Principal Accounting Officer & Chief Business Officer |
| Ms. Sumita Ray J.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-03 | 8-K | d134183d8k.htm |
| 2026-07-22 | D | |
| 2026-07-10 | 8-K | d123955d8k.htm |
| 2026-06-18 | S-3 | d44856ds3.htm |
| 2026-06-03 | S-8 | d107767ds8.htm |
| 2026-06-03 | 8-K | cue-20260601.htm |
| 2026-06-02 | 8-K | d139032d8k.htm |
| 2026-05-21 | DEF 14A | d38874ddef14a.htm |
| 2026-05-14 | D | |
| 2026-05-14 | 10-Q | cue-20260331.htm |